Author

J. Engreitz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

A. Cao· 1 shared A. L. Marsden· 1 shared B. D. Franco· 1 shared C. Fulco· 1 shared C. Pacharinsak· 1 shared D. Dorfman· 1 shared D. Heilpern-Mallory· 1 shared G. Getz· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. Cao

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High Shear Stress Reduces ERG Causing Endothelial-Mesenchymal Transition and Pulmonary Arterial Hypertension

T. Shinohara, J.-R. A. J. Moonen, Y. H. Chun, Y. C. Lee-Yow, K. Okamura, J. M. Szafron, J. Kaplan, A. Cao, L. Wang, S. Taylor, S. Isobe, M. Dong, W. Yang, K. Guo, B. D. Franco, , M. Rabinovitch

The paper shows high shear stress induces endothelial-mesenchymal transition and pulmonary arterial hypertension by reducing ERG expression, which can be mitigated by ERG replenishment.

bioRxiv · Feb 2, 2024Cell Biology

Novel mechanism of MYC deregulation in Multiple Myeloma

M. Rahmat, K. Clement, J.-B. Alberge, R. Sklavenitis-Pistofidis, R. Kodgule, C. Fulco, D. Heilpern-Mallory, K. Nilsson, D. Dorfman, J. Engreitz, G. Getz, L. Pinello, R. Ryan, I. M. Ghobrial

The paper identifies a new epigenetic mechanism of MYC deregulation in multiple myeloma through enhancer accessibility and transcription factor binding, independent of translocations or amplifications.

bioRxiv · May 19, 2023 · PreprintCancer Biology